Adenosine- and adenine-nucleotide-mediated inhibition of normal and transformed keratinocyte proliferation is dependent upon dipyridamole-sensitive adenosine transport.
Extracellular adenosine and its related nucleotides have been referred to as retaliatory metabolites that can be released into the extracellular environment during inflammation, wounding, and other pathologic states. We have previously reported that these compounds reversibly inhibit the proliferation of normal keratinocyte cultures and we now demonstrate that these compounds also arrest the proliferation of transformed keratinocytes. Although our study shows that keratinocytes express mRNA corresponding to the A2B purinoreceptors and that adenosine or AMP treatment elevates intracellular cAMP in these cells, our study also demonstrates that dipyridamole-inhibitable transport of adenosine into the keratinocyte is central to the mechanism by which adenosine and adenine nucleotides arrest proliferation in these cells. In support of this mechanism, our results demonstrate that human keratinocytes express mRNA corresponding to the recently cloned dipyridamole-sensitive human equilibrative nucleoside transporter. Interestingly, coincubation with adenosine deaminase reverses the antiproliferative action of adenosine and exerts no effect on the antiproliferative activity of the adenine nucleotides, thus supporting a model in which adenine nucleotides are enzymatically converted to adenosine and transported into the keratinocyte in a tightly coupled and adenosine-deaminase-resistant manner. Analysis of adenosine- and adenosine-monophosphate-treated keratinocytes demonstrated that quiescence is induced within 12-24 h, and fluorescence-activated cell sorter analysis suggests that treatment with these compounds may result in the inhibition of keratinocyte proliferation at both G1 and S phases of the cell cycle. In addition to their documented antiproliferative action on other cell types, adenosine, adenine nucleotides, and related analogs may also represent a potential new class of pharmacologic regulators of keratinocyte proliferation in vivo.
Brown
J R
JR
Department of Dermatology and Division of Molecular Medicine, The Oregon Health Sciences University, and Veterans Affairs Medical Center, Portland, Oregon, USA.
Cornell
K
K
Cook
P W
PW
D000227:Adenine Nucleotides / Q000494:pharmacology*; D000241:Adenosine / Q000378:metabolism / Q000494:pharmacology*; D000243:Adenosine Deaminase / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002461:Cell Line, Transformed; D000242:Cyclic AMP / Q000378:metabolism; D004176:Dipyridamole / Q000494:pharmacology*; D000078404:Epidermal Cells; D016193:G1 Phase / Q000187:drug effects; D006801:Humans; D015603:Keratinocytes / Q000166:cytology*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D058914:Purinergic Antagonists; D012333:RNA, Messenger / Q000378:metabolism; D011983:Receptors, Purinergic / Q000235:genetics; D016196:S Phase / Q000187:drug effects
D000227:Adenine Nucleotides; D010726:Phosphodiesterase Inhibitors; D058914:Purinergic Antagonists; D012333:RNA, Messenger; D011983:Receptors, Purinergic; D004176:Dipyridamole; D000242:Cyclic AMP; D000243:Adenosine Deaminase; D000241:Adenosine